At a glance
ClinicalIndex Comparison Record- ✓Age ≤21 years
- ✓Confirmed diagnosis of previously untreated Hodgkin lymphoma
- ✓Ann Arbor stage IB, IIIA, or IA/IIA with extranodal extension, multiple nodal involvement (≥3 sites), or bulky mediastinal adenopathy
- ✕Favorable risk features (excludes low-risk disease)
- ✕Unfavorable risk features (excludes high-risk disease)
- ✕Prior therapy for Hodgkin lymphoma
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Stanford V Chemotherapy With Low-Dose Tailored-Field Radiation Therapy for Intermediate Risk Pediatric Hodgkin Lymphoma
In Brief
A Phase 2 clinical trial evaluating Adriamycin®, Vinblastine, and 8 other interventions for Hodgkin's Lymphoma. Completed, enrolled 81 participants across 6 sites.
Detailed Summary
The main purpose of this protocol is to estimate the percentage of patients with intermediate risk Hodgkin lymphoma who will survive free of disease (Event-free survival) for three years after treatment with multi-agent chemotherapy (Stanford V) and low-dose, tailored-field radiation therapy. The hypothesis being studied is that this treatment will result in more than 80% of patients being alive and free of disease three years after starting treatment.
Study Details
Timeline
Interventions
Given IV on Day 1 of weeks 1, 3, 5, 7, 9 and 11.
Given IV, Day 1 of weeks 1, 3, 5, 7, 9 and 11.
Given IV, Day 1 of weeks 1, 5 and 9. Cyclophosphamide may be substituted if nitrogen mustard is unavailable.
May be substituted if nitrogen mustard is unavailable. Given on Day 1 of weeks 1, 5 and 9.
Given IV on Day 1 of weeks 2, 4, 6, 8, 10 and 12.
Given IV on Day 1 of weeks 2, 4, 6, 8, 10 and 12.
Given IV on Days 1 and 2 of weeks 1-10.
Given PO every other day of weeks 1-12.
Given subcutaneously days 3-13, 16-26, 29-39, 42-52, 55-65, and 68-78 (as clinically indicated).
Participants receive radiotherapy after completion of 12 weeks of Stanford V chemotherapy.